Darmadi, D. et al. 2024. An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review. Acta Medica Academica. 53, 1 (Apr. 2024), 46–58. DOI:https://doi.org/10.5644/ama2006-124.443.